ES2136673T3 - Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos. - Google Patents

Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.

Info

Publication number
ES2136673T3
ES2136673T3 ES94104804T ES94104804T ES2136673T3 ES 2136673 T3 ES2136673 T3 ES 2136673T3 ES 94104804 T ES94104804 T ES 94104804T ES 94104804 T ES94104804 T ES 94104804T ES 2136673 T3 ES2136673 T3 ES 2136673T3
Authority
ES
Spain
Prior art keywords
keratinocit
medicines
obtaining
growth factor
kgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94104804T
Other languages
English (en)
Inventor
Glenn F Pierce
Regina M Housley
Charles F Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2136673(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2136673T3 publication Critical patent/ES2136673T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)

Abstract

BASADOS EN EXTENSOS ESTUDIOS EN VIVO EN ANIMALES, SE HA DESCUBIERTO AHORA QUE EL KGF ESTIMULA LA PROLIFERACION, CRECIMIENTO Y DIFERENCIACION EN VARIAS CELULAS DE TEJIDO EPITELIAL, CERCA DE LOS QUERATINOCITOS. ESTE MEJOR ENTENDIMIENTO DE LOS EFECTOS BIOLOGICOS DEL KGF EN VIVO, PERMITE EL EMPLEO DE ESTE POLIPEPTIDO COMO UN AGENTE TERAPEUTICO, ADECUADAMENTE FORMULADO EN UNA COMPOSICION FARMACEUTICA, PARA EL TRATAMIENTO ESPECIFICO DE ESTADOS DE ENFERMEDAD Y CONDICIONES MEDICAS QUE AFECTAN A LOS TEJIDOS Y A ORGANOS TALES COMO LA ADNEXAE DERMICA, EL HIGADO, EL PULMON, Y EL TRACTO GASTROINTESTINAL.
ES94104804T 1993-03-26 1994-03-25 Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos. Expired - Lifetime ES2136673T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4074293A 1993-03-26 1993-03-26

Publications (1)

Publication Number Publication Date
ES2136673T3 true ES2136673T3 (es) 1999-12-01

Family

ID=21912689

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94104804T Expired - Lifetime ES2136673T3 (es) 1993-03-26 1994-03-25 Utilizacion del factor de crecimiento de los queratinocitos para la obtencion de medicamentos.

Country Status (23)

Country Link
EP (1) EP0619370B1 (es)
JP (1) JP3578761B2 (es)
KR (1) KR100390340B1 (es)
CN (1) CN1064710C (es)
AT (1) ATE183233T1 (es)
AU (1) AU707340B2 (es)
CA (1) CA2159109C (es)
CZ (1) CZ285996B6 (es)
DE (1) DE69419958T2 (es)
DK (1) DK0619370T3 (es)
ES (1) ES2136673T3 (es)
FI (1) FI954541L (es)
GR (1) GR3031509T3 (es)
HU (1) HU220641B1 (es)
IL (4) IL109122A (es)
NO (1) NO953781L (es)
NZ (1) NZ263967A (es)
RU (1) RU2146148C1 (es)
SG (1) SG49841A1 (es)
SI (1) SI0619370T1 (es)
SK (1) SK281674B6 (es)
UA (1) UA46706C2 (es)
WO (1) WO1994023032A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
CN1168678A (zh) * 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
ATE241639T1 (de) * 1995-02-14 2003-06-15 Human Genome Sciences Inc Keratinozyten-wachstumsfaktor 2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
GB9619660D0 (en) * 1996-09-20 1996-11-06 Scient Hospital Suppl Int Ltd Prevention of gastrointestinal damage
EP0941110B1 (en) * 1996-10-15 2004-02-18 Amgen Inc., Uses of keratinocyte growth factor-2
EP1452205B1 (en) * 1996-10-15 2007-11-28 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6228839B1 (en) * 1997-12-19 2001-05-08 Emory University Use of keratinocyte growth factor to improve oxidative status
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
KR20010033484A (ko) 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
US6599879B1 (en) 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
US20020061304A1 (en) 2000-03-20 2002-05-23 Pfizer Products Inc. & Osi Pharmaceuticals, Inc. Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
US20040063634A1 (en) * 2001-01-19 2004-04-01 Carr Francis J. Modified kertinocyte growth factor (kgf) with reduced immunogenicity
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
RU2243784C2 (ru) * 2003-02-25 2005-01-10 Козлов Владимир Александрович Способ лечения больных хроническим гепатитом
EP1789138A2 (en) * 2004-09-13 2007-05-30 University Of Southampton Growth factor treatment for asthma
RU2391990C1 (ru) * 2008-11-25 2010-06-20 Александр Сергеевич Ботин Композиция для стимулирования роста и регенерации клеток, (варианты), а также способ ее получения (варианты)
CN101822821B (zh) * 2010-04-27 2013-01-23 复旦大学附属中山医院 角质细胞生长因子-2在制备防治肺损伤的药物中的应用
CN104707164B (zh) * 2015-03-31 2017-01-18 中国人民解放军军事医学科学院基础医学研究所 一种复合壳聚糖水凝胶敷料及其制备方法和应用
CN106226511B (zh) * 2016-07-28 2018-04-06 苏州金盟生物技术有限公司 一种重组人角质细胞生长因子生物学活性检测方法
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途
WO2020111047A1 (ja) 2018-11-27 2020-06-04 株式会社海月研究所 頭皮頭髪用組成物
KR20210114646A (ko) * 2020-03-11 2021-09-24 (주)메디코스바이오텍 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20022681B (en) * 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
CA2081104A1 (en) * 1991-02-22 1992-08-23 Glenn Pierce Use of gm-csf and g-csf to promote accelerated wound healing

Also Published As

Publication number Publication date
HU220641B1 (hu) 2002-03-28
JP2002526026A (ja) 2002-08-13
IL161568A0 (en) 2004-09-27
FI954541A0 (fi) 1995-09-25
CA2159109A1 (en) 1994-10-13
NZ263967A (en) 2005-02-25
SI0619370T1 (en) 1999-10-31
CA2159109C (en) 2004-11-16
DK0619370T3 (da) 2000-02-28
RU2146148C1 (ru) 2000-03-10
IL109122A0 (en) 1994-06-24
JP3578761B2 (ja) 2004-10-20
SK281674B6 (sk) 2001-06-11
WO1994023032A1 (en) 1994-10-13
CN1064710C (zh) 2001-04-18
FI954541A7 (fi) 1995-11-23
IL137581A (en) 2009-09-01
KR100390340B1 (ko) 2003-09-26
AU707340B2 (en) 1999-07-08
IL109122A (en) 2004-07-25
NO953781D0 (no) 1995-09-25
SG49841A1 (en) 1998-06-15
NO953781L (no) 1995-11-27
HU9502800D0 (en) 1995-12-28
CZ248295A3 (en) 1996-12-11
CN1217022A (zh) 1999-05-19
EP0619370B1 (en) 1999-08-11
ATE183233T1 (de) 1999-08-15
DE69419958D1 (de) 1999-09-16
DE69419958T2 (de) 2000-04-20
EP0619370A1 (en) 1994-10-12
HUT72711A (en) 1996-05-28
GR3031509T3 (en) 2000-01-31
KR960701204A (ko) 1996-02-24
CZ285996B6 (cs) 1999-12-15
SK118595A3 (en) 1996-11-06
UA46706C2 (uk) 2002-06-17
IL137581A0 (en) 2001-07-24
FI954541L (fi) 1995-11-23
AU6524394A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
FI954541A0 (fi) Keratinosyyttikasvutekijän terapeuttisia käyttöjä
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
BRPI0415752A (pt) métodos, composições e dispositivos para indução de estase em células, tecidos, órgãos e organismos
NO955361L (no) Organiske aerogeler
ES2080837T3 (es) Tratamiento de estados y enfermedades.
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
FI972744A0 (fi) Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa
ES2073277T3 (es) Sustancias de naturaleza polipeptida utiles en la terapia humana.
TW200635948A (en) Tripeptide and tetrapeptide thioethers
ES2150902T3 (es) Procedimientos para potenciar la cicatrizacion de heridas y la reparacion de tejidos.
PT1124577E (pt) Utilizacao de uma proteina ompa de enterobacteria para o direccionamento especifico para as celulas apresentadoras de antigenios
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
ATE113829T1 (de) Pharmazeutische zusammensetzung.
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
WO2023133053A3 (en) Methods and compositions for inducing ferroptosis in vivo
Winter et al. Incus homograft viability in cats
WIRTHS Life sciences laboratories in Spacelab
AR008362A1 (es) Formas farmaceuticas de eritropoyetina humana recombinante, y procedimientos de liofilizacion para su obtencion
CO5310552A1 (es) Compuestos para la terapia y el diagnostico de cancer de pulmon y metodos de uso de los mismos
UA28342A (uk) Спосіб одержання біологічно активної речовини для лікування серцевих захворювань
ATE329613T1 (de) Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas
ES2181586B1 (es) Producto farmaceutico para el tratamiento de tumores cancerigenos.
MX9708989A (es) Terapia de celulas alogeneicas para el cancer despues del transplante de celulas madre alogeneicas.
CU22613A1 (es) Uso de factor de crecimiento epidérmico para el tratamiento del acne
CO5300456A1 (es) Compuestos y metodos para el tratamiento y diagnostico del cancer de prostata

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 619370

Country of ref document: ES